Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;37(8):1753-1756.
doi: 10.1038/s41375-023-01964-3. Epub 2023 Jul 8.

Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Mark Gurney  1 , Abhishek A Mangaonkar  1 , Terra Lasho  1 , Christy Finke  1 , Aref Al-Kali  1 , Naseema Gangat  1 , Mithun V Shah  1 , Hassan B Alkhateeb  1 , Ayalew Tefferi  1 , David Sallman  2 , Zhuoer Xie  2 , David Viswanatha  3 , Kaaren Reichard  3 , Najla Al Ali  2 , Rami Komrokji  2 , Eric Padron  4 , Mrinal M Patnaik  5
Affiliations

Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Mark Gurney et al. Leukemia. 2023 Aug.
No abstract available

PubMed Disclaimer

References

    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. - DOI - PubMed - PMC
    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. - DOI - PubMed
    1. Cumbo C, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. TP53 in myelodysplastic syndromes: recent biological and clinical findings. Int J Mol Sci. 2020;21. https://doi.org/10.3390/IJMS21103432 .
    1. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705–11. - DOI - PubMed
    1. Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, et al. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023;108:150–60. - DOI - PubMed

LinkOut - more resources